|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1)
|
 |
 |
 |
 |
 |
Deoxynucleoside triphosphate
|
+
|
DNA(n)
|
=
|
diphosphate
|
+
|
DNA(n+1)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B:
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1)
|
 |
 |
 |
 |
 |
Deoxynucleoside triphosphate
|
+
|
DNA(n)
|
=
|
diphosphate
|
+
|
DNA(n+1)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B:
E.C.3.1.13.2
- Exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B:
E.C.3.1.26.13
- Retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
Chains A, B:
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
RNA-dependent DNA replication
|
1 term
|
 |
|
Biochemical function
|
nucleic acid binding
|
4 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
4:853-860
(1996)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
|
|
Y.Hsiou,
J.Ding,
K.Das,
A.D.Clark,
S.H.Hughes,
E.Arnold.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: HIV-1 reverse transcriptase (RT) is a major target for anti-HIV
drugs. A considerable amount of information about the structure of RT is
available, both unliganded and in complex with template-primer or non-nucleoside
RT inhibitors (NNRTIs). But significant conformational differences in the p66
polymerase domain among the unliganded structures have complicated the
interpretation of these data, leading to different proposals for the mechanisms
of polymerization and inhibition. RESULTS: We report the structure of an
unliganded RT at 2.7 A resolution, crystallized in space group C2 with a crystal
packing similar to that of the RT-NNRTI complexes. The p66 thumb subdomain is
folded into the DNA-binding cleft. Comparison of the unliganded RT structures
with the DNA-bound RT and the NNRTI-bound RT structures reveals that the p66
thumb subdomain can exhibit two different upright conformations. In the
DNA-bound RT, the p66 thumb subdomain adopts an upright position that can be
described as resulting from a rigid-body rotation of the p66 thumb along the
"thumb's knuckle' located near residues Trp239 (in strand beta 14) and
Val317 (in beta 15) compared with the thumb position in the unliganded RT
structure. NNRTI binding induces an additional hinge movement of the p66 thumb
near the thumb's knuckle, causing the p66 thumb to adopt a configuration that is
even more extended than in the DNA-bound RT structure. CONCLUSIONS: The p66
thumb subdomain is extremely flexible. NNRTI binding induces both short-range
and long-range structural distortions in several domains of RT, which are
expected to alter the position and conformation of the template-primer. These
changes may account for the inhibition of polymerization and the alteration of
the cleavage specificity of RNase H by NNRTI binding.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Superposition of (a) unliganded RT and RT–DNA–Fab
complex and (b) unliganded RT and RT–α-APA
(α-anilinophenylacetamide) complex based on 89 Cα atoms in the
p66 palm subdomain, including the β6–β10–β9 region. The
unliganded RT is shown in red, RT–α-APA in blue, and
RT–DNA–Fab in green. A comparison of the two superpositions
reveals that NNRTI binding appears to be accompanied by a
long-range distortion that is coupled with a hinge motion
(indicated by curved arrows) between the β6–β10–β9 and
β12–β13–β14 sheets at the p66 palm subdomain (within the
circle). The different positions of the thumb in different HIV-1
RT structures supports the idea that this subdomain could play
a role during polymerization. Figure 3. Superposition of (a)
unliganded RT and RT–DNA–Fab complex and (b) unliganded RT
and RT–α-APA (α-anilinophenylacetamide) complex based on 89
Cα atoms in the p66 palm subdomain, including the
β6–β10–β9 region. The unliganded RT is shown in red,
RT–α-APA in blue, and RT–DNA–Fab in green. A comparison
of the two superpositions reveals that NNRTI binding appears to
be accompanied by a long-range distortion that is coupled with a
hinge motion (indicated by curved arrows) between the
β6–β10–β9 and β12–β13–β14 sheets at the p66 palm
subdomain (within the circle). The different positions of the
thumb in different HIV-1 RT structures supports the idea that
this subdomain could play a role during polymerization.
|
 |
Figure 4.
Figure 4. Stereoview of a portion of a (2mF[obs]–F[calc])
difference Fourier map at the p66 connection subdomain, at 2.7
å resolution. The phases were computed from the current
atomic model and the map is contoured at 1.4σ. The side chain
and the carboxyl groups are well defined in the electron density
map. Figure 4. Stereoview of a portion of a
(2mF[obs]–F[calc]) difference Fourier map at the p66
connection subdomain, at 2.7 å resolution. The phases were
computed from the current atomic model and the map is contoured
at 1.4σ. The side chain and the carboxyl groups are well
defined in the electron density map.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(1996,
4,
853-860)
copyright 1996.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Herschhorn,
and
A.Hizi
(2010).
Retroviral reverse transcriptases.
|
| |
Cell Mol Life Sci, 67,
2717-2747.
|
 |
|
|
|
|
 |
A.J.Kandathil,
A.P.Joseph,
R.Kannangai,
N.Srinivasan,
O.C.Abraham,
S.A.Pulimood,
and
G.Sridharan
(2010).
HIV reverse transcriptase: Structural interpretation of drug resistant genetic variants from India.
|
| |
Bioinformation, 4,
36-45.
|
 |
|
|
|
|
 |
A.K.Upadhyay,
T.T.Talele,
and
V.N.Pandey
(2010).
Impact of template overhang-binding region of HIV-1 RT on the binding and orientation of the duplex region of the template-primer.
|
| |
Mol Cell Biochem, 338,
19-33.
|
 |
|
|
|
|
 |
G.J.van Westen,
J.K.Wegner,
A.Bender,
A.P.Ijzerman,
and
H.W.van Vlijmen
(2010).
Mining protein dynamics from sets of crystal structures using "consensus structures".
|
| |
Protein Sci, 19,
742-752.
|
 |
|
|
|
|
 |
K.Singh,
B.Marchand,
K.A.Kirby,
E.Michailidis,
and
S.G.Sarafianos
(2010).
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.
|
| |
Viruses, 2,
606-638.
|
 |
|
|
|
|
 |
M.E.Abram,
S.G.Sarafianos,
and
M.A.Parniak
(2010).
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site.
|
| |
Retrovirology, 7,
6.
|
 |
|
|
|
|
 |
M.Götte,
J.W.Rausch,
B.Marchand,
S.Sarafianos,
and
S.F.Le Grice
(2010).
Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.
|
| |
Biochim Biophys Acta, 1804,
1202-1212.
|
 |
|
|
|
|
 |
R.Hu,
F.Barbault,
F.Maurel,
M.Delamar,
and
R.Zhang
(2010).
Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies.
|
| |
Chem Biol Drug Des, 76,
518-526.
|
 |
|
|
|
|
 |
S.Ganguly,
S.Murugesan,
N.Prasanthi,
O.Alptürk,
B.Herman,
and
N.Sluis-Cremer
(2010).
Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.
|
| |
Lett Drug Des Discov, 7,
318-323.
|
 |
|
|
|
|
 |
V.A.Braz,
L.A.Holladay,
and
M.D.Barkley
(2010).
Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
|
| |
Biochemistry, 49,
601-610.
|
 |
|
|
|
|
 |
X.Tu,
K.Das,
Q.Han,
J.D.Bauman,
A.D.Clark,
X.Hou,
Y.V.Frenkel,
B.L.Gaffney,
R.A.Jones,
P.L.Boyer,
S.H.Hughes,
S.G.Sarafianos,
and
E.Arnold
(2010).
Structural basis of HIV-1 resistance to AZT by excision.
|
| |
Nat Struct Mol Biol, 17,
1202-1209.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Agopian,
E.Gros,
G.Aldrian-Herrada,
N.Bosquet,
P.Clayette,
and
G.Divita
(2009).
A New Generation of Peptide-based Inhibitors Targeting HIV-1 Reverse Transcriptase Conformational Flexibility.
|
| |
J Biol Chem, 284,
254-264.
|
 |
|
|
|
|
 |
C.F.Venezia,
B.J.Meany,
V.A.Braz,
and
M.D.Barkley
(2009).
Kinetics of association and dissociation of HIV-1 reverse transcriptase subunits.
|
| |
Biochemistry, 48,
9084-9093.
|
 |
|
|
|
|
 |
D.M.Himmel,
K.A.Maegley,
T.A.Pauly,
J.D.Bauman,
K.Das,
C.Dharia,
A.D.Clark,
K.Ryan,
M.J.Hickey,
R.A.Love,
S.H.Hughes,
S.Bergqvist,
and
E.Arnold
(2009).
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.
|
| |
Structure, 17,
1625-1635.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.J.Zhang,
Y.X.Wang,
H.Wu,
D.Y.Jin,
Y.M.Wen,
and
B.J.Zheng
(2009).
The y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stability.
|
| |
PLoS One, 4,
e6108.
|
 |
|
|
|
|
 |
J.M.Seckler,
K.J.Howard,
M.D.Barkley,
and
P.L.Wintrode
(2009).
Solution structural dynamics of HIV-1 reverse transcriptase heterodimer.
|
| |
Biochemistry, 48,
7646-7655.
|
 |
|
|
|
|
 |
M.D.Cullen,
W.C.Ho,
J.D.Bauman,
K.Das,
E.Arnold,
T.L.Hartman,
K.M.Watson,
R.W.Buckheit,
C.Pannecouque,
E.De Clercq,
and
M.Cushman
(2009).
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
|
| |
J Med Chem, 52,
6467-6473.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.G.Sarafianos,
B.Marchand,
K.Das,
D.M.Himmel,
M.A.Parniak,
S.H.Hughes,
and
E.Arnold
(2009).
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.
|
| |
J Mol Biol, 385,
693-713.
|
 |
|
|
|
|
 |
D.T.Jayaweera,
L.Espinoza,
and
J.Castro
(2008).
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
|
| |
Expert Opin Pharmacother, 9,
3083-3094.
|
 |
|
|
|
|
 |
J.D.Bauman,
K.Das,
W.C.Ho,
M.Baweja,
D.M.Himmel,
A.D.Clark,
D.A.Oren,
P.L.Boyer,
S.H.Hughes,
A.J.Shatkin,
and
E.Arnold
(2008).
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.
|
| |
Nucleic Acids Res, 36,
5083-5092.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.L.Coté,
and
M.J.Roth
(2008).
Murine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptase.
|
| |
Virus Res, 134,
186-202.
|
 |
|
|
|
|
 |
M.Radi,
C.Falciani,
L.Contemori,
E.Petricci,
G.Maga,
A.Samuele,
S.Zanoli,
M.Terrazas,
M.Castria,
A.Togninelli,
J.A.Esté,
I.Clotet-Codina,
M.Armand-Ugón,
and
M.Botta
(2008).
A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs.
|
| |
ChemMedChem, 3,
573-593.
|
 |
|
|
|
|
 |
F.Ceccherini-Silberstein,
V.Svicher,
T.Sing,
A.Artese,
M.M.Santoro,
F.Forbici,
A.Bertoli,
S.Alcaro,
G.Palamara,
A.d'Arminio Monforte,
J.Balzarini,
A.Antinori,
T.Lengauer,
and
C.F.Perno
(2007).
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
|
| |
J Virol, 81,
11507-11519.
|
 |
|
|
|
|
 |
P.M.Collins,
K.I.Hidari,
and
H.Blanchard
(2007).
Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols.
|
| |
Acta Crystallogr D Biol Crystallogr, 63,
415-419.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Xia,
J.Radzio,
K.S.Anderson,
and
N.Sluis-Cremer
(2007).
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
|
| |
Protein Sci, 16,
1728-1737.
|
 |
|
|
|
|
 |
C.Dash,
T.S.Fisher,
V.R.Prasad,
and
S.F.Le Grice
(2006).
Examining interactions of HIV-1 reverse transcriptase with single-stranded template nucleotides by nucleoside analog interference.
|
| |
J Biol Chem, 281,
27873-27881.
|
 |
|
|
|
|
 |
D.M.Himmel,
S.G.Sarafianos,
S.Dharmasena,
M.M.Hossain,
K.McCoy-Simandle,
T.Ilina,
A.D.Clark,
J.L.Knight,
J.G.Julias,
P.K.Clark,
K.Krogh-Jespersen,
R.M.Levy,
S.H.Hughes,
M.A.Parniak,
and
E.Arnold
(2006).
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.
|
| |
ACS Chem Biol, 1,
702-712.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Ceccherini-Silberstein,
F.Gago,
M.Santoro,
C.Gori,
V.Svicher,
F.Rodríguez-Barrios,
R.d'Arrigo,
M.Ciccozzi,
A.Bertoli,
A.d'Arminio Monforte,
J.Balzarini,
A.Antinori,
and
C.F.Perno
(2005).
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
|
| |
J Virol, 79,
10718-10729.
|
 |
|
|
|
|
 |
M.Skasko,
K.K.Weiss,
H.M.Reynolds,
V.Jamburuthugoda,
K.Lee,
and
B.Kim
(2005).
Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases.
|
| |
J Biol Chem, 280,
12190-12200.
|
 |
|
|
|
|
 |
E.N.Peletskaya,
A.A.Kogon,
S.Tuske,
E.Arnold,
and
S.H.Hughes
(2004).
Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
|
| |
J Virol, 78,
3387-3397.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.A.Locatelli,
G.Campiani,
R.Cancio,
E.Morelli,
A.Ramunno,
S.Gemma,
U.Hübscher,
S.Spadari,
and
G.Maga
(2004).
Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.
|
| |
Antimicrob Agents Chemother, 48,
1570-1580.
|
 |
|
|
|
|
 |
J.D.Pata,
W.G.Stirtan,
S.W.Goldstein,
and
T.A.Steitz
(2004).
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.
|
| |
Proc Natl Acad Sci U S A, 101,
10548-10553.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Sluis-Cremer,
N.A.Temiz,
and
I.Bahar
(2004).
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
|
| |
Curr HIV Res, 2,
323-332.
|
 |
|
|
|
|
 |
Z.Zhou,
and
J.D.Madura
(2004).
Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
|
| |
Proteins, 57,
493-503.
|
 |
|
|
|
|
 |
J.A.Bruenn
(2003).
A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases.
|
| |
Nucleic Acids Res, 31,
1821-1829.
|
 |
|
|
|
|
 |
L.Shen,
J.Shen,
X.Luo,
F.Cheng,
Y.Xu,
K.Chen,
E.Arnold,
J.Ding,
and
H.Jiang
(2003).
Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.
|
| |
Biophys J, 84,
3547-3563.
|
 |
|
|
|
|
 |
N.Sluis-Cremer,
E.Kempner,
and
M.A.Parniak
(2003).
Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis.
|
| |
Protein Sci, 12,
2081-2086.
|
 |
|
|
|
|
 |
J.Lindberg,
S.Sigurdsson,
S.Löwgren,
H.O.Andersson,
C.Sahlberg,
R.Noréen,
K.Fridborg,
H.Zhang,
and
T.Unge
(2002).
Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.
|
| |
Eur J Biochem, 269,
1670-1677.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Wisniewski,
Y.Chen,
M.Balakrishnan,
C.Palaniappan,
B.P.Roques,
P.J.Fay,
and
R.A.Bambara
(2002).
Substrate requirements for secondary cleavage by HIV-1 reverse transcriptase RNase H.
|
| |
J Biol Chem, 277,
28400-28410.
|
 |
|
|
|
|
 |
N.A.Temiz,
and
I.Bahar
(2002).
Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase.
|
| |
Proteins, 49,
61-70.
|
 |
|
|
|
|
 |
N.Sluis-Cremer,
and
G.Tachedjian
(2002).
Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.
|
| |
Eur J Biochem, 269,
5103-5111.
|
 |
|
|
|
|
 |
P.Constans
(2002).
Linear scaling approaches to quantum macromolecular similarity: evaluating the similarity function.
|
| |
J Comput Chem, 23,
1305-1313.
|
 |
|
|
|
|
 |
S.G.Sarafianos,
A.D.Clark,
K.Das,
S.Tuske,
J.J.Birktoft,
P.Ilankumaran,
A.R.Ramesha,
J.M.Sayer,
D.M.Jerina,
P.L.Boyer,
S.H.Hughes,
and
E.Arnold
(2002).
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.
|
| |
EMBO J, 21,
6614-6624.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.Zhou,
M.Madrid,
and
J.D.Madura
(2002).
Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
|
| |
Proteins, 49,
529-542.
|
 |
|
|
|
|
 |
E.Doo,
and
T.J.Liang
(2001).
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.
|
| |
Gastroenterology, 120,
1000-1008.
|
 |
|
|
|
|
 |
E.N.Peletskaya,
P.L.Boyer,
A.A.Kogon,
P.Clark,
H.Kroth,
J.M.Sayer,
D.M.Jerina,
and
S.H.Hughes
(2001).
Cross-linking of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase to template-primer.
|
| |
J Virol, 75,
9435-9445.
|
 |
|
|
|
|
 |
G.Tachedjian,
M.Orlova,
S.G.Sarafianos,
E.Arnold,
and
S.P.Goff
(2001).
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
|
| |
Proc Natl Acad Sci U S A, 98,
7188-7193.
|
 |
|
|
|
|
 |
K.Das,
X.Xiong,
H.Yang,
C.E.Westland,
C.S.Gibbs,
S.G.Sarafianos,
and
E.Arnold
(2001).
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
|
| |
J Virol, 75,
4771-4779.
|
 |
|
|
|
|
 |
M.A.Shogren-Knaak,
P.J.Alaimo,
and
K.M.Shokat
(2001).
Recent advances in chemical approaches to the study of biological systems.
|
| |
Annu Rev Cell Dev Biol, 17,
405-433.
|
 |
|
|
|
|
 |
E.K.Halvas,
E.S.Svarovskaia,
E.O.Freed,
and
V.K.Pathak
(2000).
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
|
| |
J Virol, 74,
6669-6674.
|
 |
|
|
|
|
 |
E.K.Halvas,
E.S.Svarovskaia,
and
V.K.Pathak
(2000).
Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity.
|
| |
J Virol, 74,
10349-10358.
|
 |
|
|
|
|
 |
E.S.Svarovskaia,
K.A.Delviks,
C.K.Hwang,
and
V.K.Pathak
(2000).
Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.
|
| |
J Virol, 74,
7171-7178.
|
 |
|
|
|
|
 |
G.Maga,
D.Ubiali,
R.Salvetti,
M.Pregnolato,
and
S.Spadari
(2000).
Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
|
| |
Antimicrob Agents Chemother, 44,
1186-1194.
|
 |
|
|
|
|
 |
H.Huang,
S.C.Harrison,
and
G.L.Verdine
(2000).
Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond.
|
| |
Chem Biol, 7,
355-364.
|
 |
|
|
|
|
 |
H.Jonckheere,
J.Anné,
and
E.De Clercq
(2000).
The HIV-1 reverse transcription (RT) process as target for RT inhibitors.
|
| |
Med Res Rev, 20,
129-154.
|
 |
|
|
|
|
 |
L.T.Bacheler
(1999).
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
|
| |
Drug Resist Updat, 2,
56-67.
|
 |
|
|
|
|
 |
M.Madrid,
A.Jacobo-Molina,
J.Ding,
and
E.Arnold
(1999).
Major subdomain rearrangement in HIV-1 reverse transcriptase simulated by molecular dynamics.
|
| |
Proteins, 35,
332-337.
|
 |
|
|
|
|
 |
S.G.Sarafianos,
K.Das,
A.D.Clark,
J.Ding,
P.L.Boyer,
S.H.Hughes,
and
E.Arnold
(1999).
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.
|
| |
Proc Natl Acad Sci U S A, 96,
10027-10032.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.G.Sarafianos,
K.Das,
J.Ding,
P.L.Boyer,
S.H.Hughes,
and
E.Arnold
(1999).
Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site.
|
| |
Chem Biol, 6,
R137-R146.
|
 |
|
|
|
|
 |
A.D.Frankel,
and
J.A.Young
(1998).
HIV-1: fifteen proteins and an RNA.
|
| |
Annu Rev Biochem, 67,
1.
|
 |
|
|
|
|
 |
D.Sun,
S.Jessen,
C.Liu,
X.Liu,
S.Najmudin,
and
M.M.Georgiadis
(1998).
Cloning, expression, and purification of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase: crystallization of nucleic acid complexes.
|
| |
Protein Sci, 7,
1575-1582.
|
 |
|
|
|
|
 |
D.V.Nissley,
P.L.Boyer,
D.J.Garfinkel,
S.H.Hughes,
and
J.N.Strathern
(1998).
Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.
|
| |
Proc Natl Acad Sci U S A, 95,
13905-13910.
|
 |
|
|
|
|
 |
P.L.Boyer,
H.Q.Gao,
and
S.H.Hughes
(1998).
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.
|
| |
Antimicrob Agents Chemother, 42,
447-452.
|
 |
|
|
|
|
 |
J.Ding,
S.H.Hughes,
and
E.Arnold
(1997).
Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer.
|
| |
Biopolymers, 44,
125-138.
|
 |
|
|
|
|
 |
J.R.Kiefer,
C.Mao,
C.J.Hansen,
S.L.Basehore,
H.H.Hogrefe,
J.C.Braman,
and
L.S.Beese
(1997).
Crystal structure of a thermostable Bacillus DNA polymerase I large fragment at 2.1 A resolution.
|
| |
Structure, 5,
95.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Taube,
O.Avidan,
and
A.Hizi
(1997).
The fidelity of misinsertion and mispair extension throughout DNA synthesis exhibited by mutants of the reverse transcriptase of human immunodeficiency virus type 2 resistant to nucleoside analogs.
|
| |
Eur J Biochem, 250,
106-114.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|